New Blood Sugar Powered Implant Offers Innovative Diabetes Treatment Option

Researchers have developed NeuroAxis, an implantable device that uses excess blood sugar as fuel to deliver targeted electrical therapy to the vagus nerve, successfully treating diabetes in rats.

New Blood Sugar Powered Implant Offers Innovative Diabetes Treatment Option
Photo-illustration WireIsrael: AI Generated

Medical device batteries remain a persistent challenge in implantable technology, often requiring surgical replacements over time. Researchers from Singapore and China have unveiled a novel approach for diabetes management that bypasses traditional batteries entirely by utilizing excess blood sugar as an energy source.

The Mechanics of the NeuroAxis Implant

Described in the journal Nature, the device named NeuroAxis was developed by a team from the National University of Singapore led by Prof. Ouyang Jiyuan alongside Prof. Wang Lianhui's team at the Nanjing University of Posts and Telecommunications. At the core of the implant lies a miniature fuel cell that breaks down glucose to generate electricity, mimicking how nerve cells derive energy from sugar. Higher blood sugar concentrations yield greater electrical output, allowing the device's electronic circuit to monitor these levels.

When the electrical signal crosses a specific threshold, the implant delivers electrical pulses to the vagus nerve, which connects the brain to internal organs and regulates metabolism and inflammatory responses. Consequently, the same glucose serves simultaneously as the fuel and the switch. Conventional nerve stimulators operate on fixed schedules regardless of physiological conditions, which can trigger side effects like reduced heart rates or gastrointestinal discomfort. NeuroAxis functions exclusively when needed and requires no batteries or wireless recharging.

Promising Results in Animal Studies

In preclinical trials involving rats with type 2 diabetes models characterized by obesity, insulin resistance, and chronic inflammation, the implant reduced food intake, body weight, and abdominal fat. After just two weeks, blood glucose levels nearly normalized to those of healthy subjects, and insulin sensitivity improved significantly. In models of type 1 diabetes, the therapy promoted the recovery of insulin-producing beta cells and suppressed inflammatory responses. According to the research team, therapeutic effects persisted even after treatment concluded.

This development parallels other recent laboratory advancements. Researchers at ETH Zurich recently detailed a separate implant in the journal Science designed to clear excess blood sugar by converting it into substances excreted by the kidneys. While both technologies are currently restricted to rodent models and remain years away from human clinical trials, the race to engineer implantable alternatives to daily injections is accelerating.

Dr. Juntao Imai of Tohoku University in Japan, who authored an accompanying commentary in the Nature publication, described the study as an important proof of concept that advances diabetes device development. Significant engineering challenges remain before human application becomes feasible, including scaling power output for human metabolism and ensuring long-term biocompatibility within the body.

Related News